Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Endogenous Catecholamine
|
Agonist of α and β receptors; positive ionotropic (contractility) and chronotropic (rate) on heart (β1), vasoconstriction in vascular beds (α), and vasodilation in skeletal muscle blood vessels (β2) which may lower TPR
|
tachycardia, arrhythmia, anxiety, hypertension, and acute pulmonary edema
|
Cardiac arrest (increases cardiac output), anaphylaxis
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Endogenous catecholamine
|
Agonist of α1, α2, and β1 receptors but little effect on β2; increases TPR and BP, positive ionotropic effect on heart
|
Ischemia, arrhythmias
|
Hypotension, ADHD, depression
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Endogenous Catecholamine
|
Activates D1 receptors causing vasodilation of renal, splanchnic, coronary, cerebral, and other resistance vessels. Activation of D2 receptors suppresses norepinephrine release. Also activates β1receptors in heart and at high concentrations α receptors leading to vasoconstriction. Regulates Na+ secretion and renal function. Neurotransmitter in the CNS and is involved in reward system of addiction.
|
Hypotension at high doses
|
Parkinson’s disease (caused by a deficiency of dopamine in basal ganglia); Dopamine receptors are targets for antipsychotic drugs
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Direct-Acting Sympathomimetic
|
α1 agonist; vasoconstriction = ↑ arterial resistance and ↓ venous capacity, ↑ stroke volume causes ↑ CO, ↑ BP may cause reflexive ↓ HR; α1 r’s also constrict pupillary dilator muscle
|
hypertension
|
Decongestant, mydriatic (dilates pupil), can be used to increase BP
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Direct-Acting Sympathomimetic
|
α2 agonist; cause vasoconstriction when given locally, but systemically acts through CNS to decrease sympathetic tone and BP
|
Dry mouth, sedation
Drowsiness
Impaired ejaculation
|
hypertension
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Direct-Acting Sympathomimetic
|
α agonist with affinity for α2A receptor; promotes vasoconstriction of nasal mucosa
|
Hypotension (central Clonidine-like effect)
|
Topical decongestant
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Direct-Acting Sympathomimetic
|
Potent β1 and β2 agonist, positive chronotropic and ionotropic effects, vasodilator = ↑ CO, ↓ TPR and ↓ BP
|
Tachycardia, dysrhythmias
|
Bradycardia, heart block
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Direct-Acting Sympathomimetic
|
Β1 agonist; activate β1 receptors causing ↑ CO with less reflexive tachycardia because they do not activate vasodilator β2 receptors
|
Hypertension, arrhythmias
|
Heart failure, cardiogenic shock
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Mixed-Acting Sympathomimetic
|
Indirect stimulation of the adrenergic receptor system by increasing the activity of noradrenaline at α- and β-receptors, ability to cross blood-brain barrier into CNS makes it a mild stimulant
|
Tachycardia, arrhythmias, various nervous system symptoms
|
Ma huang (herbal medicine) decongestant, bronchodilator, weight loss
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Indirect-Acting Sympathomimetics
|
Acts as both a norepinephrine transporter (NET) substrate and reuptake blocker, eliciting reverse transport and blocking normal uptake = ↑ NE in synaptic cleft; release of NE and some dopamine; similar to ephedrine but enters CNS more readily
|
Elevates CO and BP
CNS stimulation
|
Marked stimulant effect on mood and alertness and depressant effect on appetite
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Indirect-Acting Sympathomimetics
|
Pharmacologic effects and abuse potential are similar to amphetamine (p.141); Block NET-mediated NE reuptake and enhance NE signaling similar to cocaine (p. 133) ???
|
Nervousness, drowsiness, insomnia
|
ADHD, narcolepsy
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Indirect-Acting Sympathomimetics
|
Inhibits both norepinephrine and dopamine transporters; increases interstitial concentrations not only of norepinephrine, dopamine, serotonin, and glutamate; decreases GABA levels
|
Increase in BP and HR
|
Improves wakefulness in narcolepsy and some other conditions
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Indirect-Acting Sympathomimetics
|
Indirect sympathomimetic action caused by release of stored catecholamines = action similar to NE; readily metabolized by MAO in liver = high first-pass effect
|
Increase in BP
Hypertensive crisis
|
Patients treated with monoamine oxidase (MAO) inhibitors may have intensified Tyramine effect (must avoid Tyramine containing foods like cheese)
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Catecholamine Reuptake Inhibitor
|
Inhibits transmitter reuptake at noradrenergic synapses; enters CNS and inhibits dopamine reuptake into neurons in the “pleasure centers” of the brain
|
Tachycardia, hallucinations, paranoid delusions; overdoses cause tachyarrhythmias and a marked ↑ BP, which can be life-threatening. CNS stimulation
|
Heavily abused drug - produces amphetamine-like”psychological effects that is shorter lasting and more intense
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Dopamine Agonist
|
D1 agonist; activates adenylyl cyclase; causes vascular smooth muscle relaxation
|
hypotension, reflex tachycardia, ↑ intraocular pressure
|
hypertension
|
|
|
|
Term
|
Definition
CH 9 Adrenoceptor Agonists & Sympathomimetic Drugs
Dopamine Agonist
|
D2 agonists; inhibits adenylyl cyclase and interacts with other intracellular pathways; restores dopamine actions in the CNS
|
Orthostatic hypotension
|
Parkinson’s disease, prolactinemia
|
|
|
|